Boston Scientific acquires tumor removal tech
Courtesy Boston Scientific
Boston Scientific's Global Headquarters are located in Marlborough.
Marlborough’s Boston Scientific has acquired a technology that can enhance endoscopic surgery for precancerous lesions and malignant tumors in the gastrointestinal tract.
For an undisclosed amount of money, the medical device company acquired LumenR Tissue Retractor System from LumenR LLC, a privately held Newark, California based company. The company reported that the acquisition is immaterial to earnings per share for 2016 and 2017.
The system could reduce procedure times as well as patient complications from endoscopic sub-mucosal dissection (ESD) and endoscopic mucosal resection (EMR) procedures which are less invasive alternatives to conventional surgery for the removal of precancerous lesions and malignant tumors in the gastrointestinal tract, according to Boston Scientific. The system will enable enhanced visualization of lesions and create a stable working environment to support tissue retraction and resection during these procedures, according to Boston Scientific.
"Every year, patients around the world undergo open gastrointestinal surgery that has a profound impact on their lives. By bringing this innovative technology forward, we have an opportunity for more physicians to treat patients successfully through less invasive endoscopic procedures,” said Art Butcher, senior vice president and president of endoscopy for Boston Scientific.
WBJ Web Partners
Most Recent
Most Recent
0 Comments